Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Domestic Pharma: September quarter review - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Nov 18, 2003

    Domestic Pharma: September quarter review

    The stock markets have made impressive gains since the beginning of 2003. Despite being a broad based rally, pharma stocks have been able to remain in the limelight and attract buying interest. This is evident from the following chart, which compares the BSE-Sensex with BSE-Healthcare index. As can be seen from the chart, Rs 100 invested in the above two indices on 1st January '03 would have yielded Rs 145 in case of the SENSEX, the same would have yielded Rs 163 in case of BSE-Healthcare index.

    In this article, we shall see the performance of the key pharma companies in terms of the latest declared quarterly results. For our analysis, we have considered six major domestic pharma companies (Ranbaxy, Dr Reddy's, Cipla, Wockhardt, Nicholas Piramal and Sun Pharma). Take a look at the following table.

    Quarter at a glance…
    (Rs m) July '02-Sep '02 July '03-Sep '03 Change
    Net Sales 25,453 29,183 14.7%
    Operating Profit (EBDIT) 6,109 6,356 14.7%
    Operating Profit Margin (%) 24.0% 21.8%  
    Profit after Tax/(Loss) 4,372.2 5,224.6 19.5%
    Net profit margin (%) 17.2% 17.9%  
    P/E (x) 25.6 21.4  

    After the weak showing during the first five months of 2003, the domestic pharma market saw a revival in demand. Apart from the high value lifestyle segments, even the traditional therapeutic segments like anti-infectives recorded impressive growth. It is to be noted here that anti-infectives segment had a dismal performance during April '03 – May '03, wherein this segment had recorded de-growth. During the September '03 quarter, revival in demand for traditional therapeutic segments coupled with high growth registered by lifestyle segments helped the companies under review post an impressive 13.8% growth in domestic market. The top performers in the domestic market were Cipla, Ranbaxy and Nicholas Piramal. Wockhardt and Sun Pharma on the other hand, reported disappointing domestic growth.

    On the exports front, the companies under review as a group grew by 15.6%. This was primarily due to higher bulk drug exports by Sun Pharma, Cipla and Nicholas Piramal (inorganic). Sun Pharma also recorded impressive growth in formulations export.

    On the operations front, higher investments on R&D as well advertising and promotion expenses have taken their toll on the operating margins of the group. However, it is to be noted here that with product patents coming into effect in India from 2005, Indian companies will have to increasingly focus on research and development. The increase in R&D expenditure to this extent is thus a positive for the industry as a whole. However, decline in operating profit margins was offset by a drop in interest expenses due to the debt restructuring exercise undertaken by some of the companies and a strong growth in other income.

    The domestic pharma industry (i.e., companies under review) is trading at a P/E of 21x its annualized September quarter earnings. After the slump witnessed in the early part of the year, domestic pharma market is once again recording double-digit growth. This apart, the export thrust (for generic drugs) of the Indian pharma companies is also translating into higher growth from the international markets. Given the low cost manufacturing operations of Indian pharma companies, they are also likely to benefit from manufacturing contracts likely to be outsourced by the global pharma giants.

    However, post 2005, with the implementation of product patents, Indian companies might struggle to achieve the current growth rates in the domestic market. This apart, the risks involved in R&D initiatives could also put pressure on the margins of the company going forward. Investors need to hence exercise caution and invest only in companies that have strong business models and a management that has a track record of successfully executing its plans.



    Equitymaster requests your view! Post a comment on "Domestic Pharma: September quarter review". Click here!


    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    The Power of 5 Minutes (The 5 Minute Wrapup)

    Jun 16, 2017

    Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    More Views on News

    Most Popular

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

    Aug 10, 2017

    Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    5 Steps To Become Financially Independent(Outside View)

    Aug 16, 2017

    Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 22, 2017 (Close)